|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.73 USD | +2.14% |
|
-4.43% | 0.00% |
| Apr. 15 | Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target | MT |
| Apr. 15 | William Blair Starts LENZ Therapeutics With Outperform Rating | MT |
April 3 (Reuters) - Lenz Therapeutics said on Wednesday its experimental drugs to treat loss of near vision met the main goal of a late-stage study. (Reporting by Sneha S K in Bengaluru; Editing by Shilpi Majumdar)
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 402M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
LENZ THERAPEUTICS, INC. 
